Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280096 | 0.90 | BRD4 (0.53) | BRD4LTA4HSMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL2036054 | 0.83 | — | — | |
| SCHEMBL24197361 | 0.83 | BRD4 (0.50) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL26647720 | 0.83 | BRD4 (0.50) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL15360236 | 0.82 | BRD4 (0.49) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL12156725 | 0.82 | SMN1; SMN2 (0.47) | BRD4LTA4HSMN1; SMN2GNAI3GNAO1 | |
| SCHEMBL26707325 | 0.82 | SMN1; SMN2 (0.47) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL11916766 | 0.81 | EPHX1 (0.51) | BRD4LTA4HSMN1; SMN2 | |
| SCHEMBL2607204 | 0.81 | NCF1 (0.41) | NCF1GNAI3GNAO1GNAI1 | |
| SCHEMBL23136277 | 0.81 | BRD4 (0.44) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023207101-A1 | IONIZABLE LIPID COMPOUNDS | Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| EP-4269385-A1 | IONIZABLE LIPID COMPOUNDS | Beijing Jitai Pharmaceutical Technology Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-10556906-B2 | Quinazoline compound | ASTELLAS PHARMA INC. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2019-09-26 | — | — | US | disclosed |
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-8101774-B2 | Ester derivatives and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-0581538-B1 | 4-Substituted 1,2,4-triazole derivatives | MERCK SHARP & DOHME (GB) | 1999-03-03 | — | — | EP | disclosed |
| CN-1037101-C | 4-substituted 1,2,4-triazole derivatives | MERCK SHARP & DOHME (GB) | 1998-01-21 | — | — | CN | disclosed |
| EP-0581538-A1 | 4-Substituted 1,2,4-triazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556906-B2 | Quinazoline compound | KRAS, NRAS, HRAS | BRD4 207/4885NCF1 855/4885LTA4H 3077/4885 |
| US-20190292182-A1 | QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | BRD4 207/4885NCF1 855/4885LTA4H 3077/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | BRD4 2096/4885NCF1 2865/4885LTA4H 1205/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | BRD4 1117/4885NCF1 1682/4885LTA4H 4165/4885 |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | BRD4 213/4885NCF1 1472/4885LTA4H 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.